Skip to main content

Three more years of CJR: What participating hospitals need to know

On April 29, CMS issued a final rule to extend the Comprehensive Care for Joint Replacement model by an additional three performance years. A number of modifications effective in the extension period aim to improve the model and reflect Medicare policy changes over the last several years. CMS anticipates that CJR will save the Medicare program an additional $217 million over the extension period. The following summarizes the most notable model changes:

  • Three new performance years have been added: PY 6 will include episodes that end between Oct. 1, 2021 and Dec. 31, 2022; PY 7 will include episodes that end between Jan. 1, 2023 and Dec. 31, 2023; and PY 8 will include episodes that end between Jan. 1, 2024 and Dec. 31, 2024.
  • Episode definitions under the model have been expanded to include total hip arthroplasty and total knee arthroplasty procedures performed in the hospital outpatient setting. The episode categories under the extension are site-neutral and are defined as:
    • MS-DRG 470: TKA and THA without fracture – inpatient and outpatient episodes
    • MS-DRG 522: THA with fracture – inpatient and outpatient episodes
    • MS-DRG 469: TKA, THA without fracture, total ankle replacement – inpatient episodes only
    • MS-DRG 521: THA with fracture – inpatient episodes only
  • The baseline period used to calculate regional target prices will be reduced from a three-year period to the most recently available one year of data. Calendar year 2020 will not be used as a baseline year due to impacts of the COVID-19 public health emergency. Adjustment for Medicare fee-for-service payment system changes and market trends in utilization will now be accomplished through a retrospective market trend adjustment. Additional episode-level risk adjustment will be implemented based on beneficiary dual eligibility status, age and count of hierarchal conditional categories.
  • CMS will perform a single reconciliation for each new performance year, beginning six months after the performance year ends. Compared to previous years of the model, hospitals will have greater opportunity to reduce the 3% discount factor that sets the episode target price based on composite quality score performance.
    • Good quality performance – 1% reduction in PYs 1-5; 1.5% reduction in PYs 6-8
    • Excellent quality performance – 1.5% reduction in PYs 1-5; 3% reduction in PYs 6-8
  • It is significant to note that the reduction of the discount factor by three percentage points for hospitals with the highest quality performance effectively removes the discount factor in entirety and alleviates some “race to the bottom” concerns for target prices.
  • One hundred and thirty-nine hospitals participating in the CJR model under voluntary status will be excluded from PYs 6-8. This exclusion applies to any remaining participant hospitals in the 33 voluntary Metropolitan Statistical Areas and hospitals with rural or low-volume status in the 34 mandatory MSAs.
Hospitals that remain under mandatory participation in the CJR model will have PY 6 episodes initiated by an anchor procedure furnished on or after July 4, 2021, and subsequently ending on or after Oct. 1, 2021. To get ready for the three-year extension period, hospitals should take several steps:
  • educate the joint replacement care team on the CJR model’s extension;
  • evaluate outpatient episode experience and opportunities;
  • re-engage and set goals with post-acute care partners; and
  • estimate potential performance under the new target prices.

Comments

Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le